This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Health Stocks in Motion

Updated from 2:22 p.m.

Shares of Genta (GNTA) were among the worst-performing health and pharmaceutical stocks Tuesday, falling 50% after the biopharmaceutical company said Sanofi-Aventis (SNY) ended the companies' joint development agreement.

The two companies will work together to develop Genasense, Genta's cancer drug, until May 8, 2005. After that, Genta will continue the development of the drug on its own. When the companies first entered the agreement in 2002, Aventis was seeking a late-stage development opportunity that could potentially be launched in the near term. Earlier this year, however, regulators rejected the drug with respect to melanoma. As a result, Aventis said that it could no longer support the development of Genasense. Shares of Genta traded down $1.30 to $1.30.

Fonar (FONR) rose 9.7% after the maker of MRI equipment swung to a first-quarter profit. The company posted a profit of 1 cent a share on sales of $25.1 million. A year ago the company posted a loss of 5 cents a share on sales of $13.3 million. Strong sales of the company's Upright MRI units led to the impressive first-quarter results. Shares traded up 11 cents to $1.25.

Shares of BriteSmile (BSML) fell 16.7% after the company posted weak third-quarter results and warned of a fourth-quarter shortfall as well. During the third quarter, the teeth-whitening technology company posted a loss of 24 cents a share on sales of $11.9 million. Analysts were expecting a loss of 9 cents a share on sales of $12.7 million. Looking ahead, BriteSmile forecast that fourth-quarter sales would decline both sequentially and on a year-over-year basis. Analysts had been expecting sales of $14.7 million. BriteSmile said the sales shortfall reflects soft demand experienced during the first part of the fourth quarter. Shares traded down $1.50 to $7.50.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs